<DOC>
	<DOCNO>NCT01608893</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) common sustain heart rhythm disorder associate significant symptom health problem include increase risk stroke death . Current drug therapy often ineffective associate significant side effect . Abnormalities calcium regulation cell may lead trigger AF . Emerging data suggest abnormal intracellular calcium regulation mediate ryanodine receptor heart cell may contribute AF . Recently investigator show β-blocker carvedilol commonly use treat patient heart failure , modifies calcium regulation mediate ryanodine receptor . At present drug frequently use treat AF . Therefore investigator conduct randomize trial compare carvedilol metoprolol prevention paroxysmal AF . This may result improved health quality life people suffer AF .</brief_summary>
	<brief_title>Carvedilol Prevention Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>The study population consist patient electrocardiographically document symptomatic paroxysmal AF ( ≥ 2 episode ≥ 15 min duration within six month period ) stable antiarrhythmic drug therapy . Patients exclude AF due reversible cause , persistent AF , significant heart failure life expectancy le one year . Eligible patient randomize carvedilol metoprolol follow 13 month . Randomization stratify base AF management strategy ( rate rhythm control ) . Carvedilol metoprolol initiate one month drug titration period achieve dose 25mg bid 50 mg bid respectively . AF occurrence document use event recorder . The co-primary outcome measure survival free AF one month blank period drug titration number day AF detect follow-up . Secondary outcome include event free survival first symptomatic episode AF , day symptomatic AF , time first second episode AF , proportion patient develop persistent AF , AF Severity Scale , CCS-AF symptom score , ventricular rate AF , proportion patient discontinuation assign therapy number emergency department visit hospitalization cardiovascular cause . Adverse effect need discontinue carvedilol metoprolol document . This study determine whether carvedilol safe effective prevention recurrent paroxysmal AF general population AF . Data analyze intention treat basis . Three hundred patient recruit 4 year . The sample size base estimate 20 % reduction event free survival AF ( power 0.90 , α = 0.05 ) . Patients recruit AF clinic population average 50 new referral per month 2500 referral since 's ' inception 2005 .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Must sinus rhythm enrollment ECG document symptomatic PAF ( &gt; 2 episode &gt; 15minutes duration 6 month period ) AF due reversible cause Contraindication previous significant adverse reaction Beta blocker therapy Persistent AF NYHA Class II great CHF LVEF &lt; = 35 % Life expectancy &lt; 1 year Geographic isolation Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>